Premium
P1‐073: Angiotensin‐converting enzyme gene and protein to Alzheimer's disease in Taiwanese elderly
Author(s) -
Yang Yuan-Han,
Wang Ling-Chun,
Chou Mei-Chuan,
Lai Chiou-Lian,
Liu Ching-Kuan
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.621
Subject(s) - genotype , allele , medicine , genotyping , apolipoprotein e , angiotensin converting enzyme , endocrinology , polymorphism (computer science) , biology , genetics , gene , disease , blood pressure
a significant difference in AD conversion risk by age and the presence of at least one APOE e4 allele, but no significant difference was observed for gender. As a result, separate curves were created for different age groups (split by the median at 73.5 years, providing a ‘‘younger’’ and an ‘‘older’’ group) to demonstrate the risk of AD conversion based on amnestic-MCI diagnosis and APOE genotype (APOE e4 positive or negative). Three-year risk of AD conversion across all groups ranged from 8.5% to 53.1%. Three-year AD conversion risk among individuals who are APOE e4 positive was 40.0% for the younger age group and 53.1% for the older age group, and among individuals who were APOE e4 negative, the risks were 8.5% (younger) and 27.7% (older). Conclusions: The resulting curves will be employed as part of a risk education and counseling protocol in an upcoming randomized controlled clinical trial, which aims to understand the impact of disclosing this type of risk information. Understanding the implications of communicating imminent risk is important as both APOE and MCI status represent means of identifying higher-risk individuals for future therapeutic opportunities.